6.1.2.3. laser ablation. line results achieved non-invasive superficially-invasive penile lesions, laser ablation proposed option smaller invasive lesions. typically, co2 laser resect tumour ample millimetres margin, coagulation tumour bed nd:yag laser better option provides deeper uniform tissue coagulation. healing time fastest co2 laser treatment, re-epithelization almost complete three six weeks post-treatment. greater depth tissue coagulation, healing time nd:yag laser treatment longer, often six weeks . penetration depth depends laser type settings commonly used settings 15–20 w co2 15–25 w nd:yag lasers publications provide technical details . panel’s sr, seven studies reported outcomes laser therapy invasive penile cancer limited t1 (81.2%) t2 (18.5%) disease total 389 patients . five-year rfr ranged 34.2-94%. cumulative mean 5-year rfr 69.4% (270/389). three studies reported 5-year rfr per disease stage 42.9–73.9% t1 23.5%–84.2% t2 disease. nine studies (n = 512), penile preservation rate following laser therapy 50–100% (mean 89.2%), indicating large proportion recurrences managed total amputation, raises caution use technique use likely best limited t1 tumours. tang et al., demonstrated nodal recurrence high multi-institutional cohort patients treated laser ablation monotherapy, illustrating importance pre-ablation biopsy risk stratification nodal staging. clinicians aware risk understaging result incision biopsy followed ablation vs. complete resection , advised patients informed laser therapy may result higher local recurrence rates compared surgical excision. three studies reported laser-related complications, preputial oedema dysuria reported frequently. meatal stenosis reported 7.4% post-operative bleeding 1–7% patients. three studies assessed sexual function laser treatment 46.0–56.5% men report impact sexual life. single trial including 46 men found 72% reported change erectile function, 22% reported decreased erectile function 6% reported improvement .